Merit Medical Systems, Inc. (MMSI) was upgraded by Raymond James from an ‘Outperform’ rating to a ‘Strong Buy’ rating in a research note issued on Monday. Price target raised to $20 from $16. MMSI shares recently gained 67C to $16.00. In the past 52 weeks, shares of South Jordan, Utah-based company, which designs, develops, manufactures, and markets medical devices for use in interventional and diagnostic procedures worldwide, have traded between a low of $11.41 and a high of $17.69. Shares are up 4.93% year-over-year ; down 11.54% year-to-date.
MMSI, which closed Friday at $15.33, has a total market cap of $694.87M.
Shares of Deckers Outdoor Corp. (DECK) are up $3.74 to $69.79 in morning trading, after analysts at Goldman Sachs upgraded the stock to ‘Buy’ from ‘Neutral’. DECK shares are currently priced at 17.09x this year’s forecasted earnings compared to the industry’s 23.34x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.30 and 13.50, respectively. Price/Sales for the same period is 1.44 while EPS is 4.08. Currently there are 11 analysts that rate DECK a ‘Buy’, 11 rate it a ‘Hold’. no analysts rates it a ‘Sell’. DECK has a median Wall Street price target of $86.50 with a high target of $110.00.
In the past 52 weeks, shares of the Goleta, California-based company have traded between a low of $65.65 and a high of $99.88 and are now at $69.63. Shares are down 16.00% year-over-year and 27.45% year-to-date.
Analysts at BMO Capital are out with a report this morning upgrading shares of Diamond Foods, Inc. (DMND) with an ‘Outperform’ from ‘Market Perform’ rating on valuation and business outlook. DMND shares recently gained $1.52 to $26.10. The stock is down more than 7.03% year-over-year and has lost roughly 12.93% year-to-date. In the past 52 weeks, shares of the San Francisco, California-company have traded between a low of $23.17 and a high of $35.58.
Diamond Foods which closed Friday at $24.58, has a total market cap of $819.96M.
Investment analysts at Chardan Capital Markets initiated coverage on shares of Ohr Pharmaceutical, Inc. (OHRP) in a note issued to investors on Monday. The firm set a ‘Buy’ rating and a $20 price target on the stock. In the past 52 weeks, shares of the pharmaceutical company have traded between a low of $6.01 and a high of $20.00 with the 50-day MA and 200-day MA located at $8.44 and $8.00 levels, respectively. Additionally, shares of OHRP have a Relative Strength Index (RSI) and MACD indicator of 36.95 and -0.65, respectively.
OHRP currently prints a one year loss of about 23.05% and a year-to-date loss of around 9.95%.
Telsey Advisory Group is out with a report this morning upgrading shares of Staples, Inc. (SPLS) with a ‘Market Perform’ from ‘Underperform’ rating and $18 from $12 price target, implying 50% expected return from the stock’s current price. The firm expects Starboard and other large shareholders to push Staples for a merger with Office Depot (ODP)
Staples shares are currently priced at 18.19x this year’s forecasted earnings compared to the industry’s 21.65x earnings multiple. Ticker has a PEG and forward P/E ratio of -5.33 and 17.73, respectively. Price/Sales for the same period is 0.48 while EPS is 0.93. Currently there are 1 analysts that rate SPLS a ‘Buy’, 16 rate it a ‘Hold’. 3 analysts rates it a ‘Sell’. SPLS has a median Wall Street price target of $14.00 with a high target of $21.00.
In the past 52 weeks, shares of the Framingham, Massachusetts-based company have traded between a low of $10.70 and a high of $18.33 and are now at $16.93. Shares are up 31.86% year-over-year ; down 5.91% year-to-date.